Sun Pharma to acquire US-listed Organon for $11.75 billion in one of India’s largest pharma deals
Sun Pharmaceutical Industries Ltd has agreed to acquire US-based Organon & Co for $11.75 billion in an all-cash deal. This significant outbound acquisition is expected to close in early 2027, strengthening Sun Pharma's global presence in women's health and biosimilars.
Sun Pharmaceutical Industries Ltd has agreed to acquire US-based Organon & Co for $11.75 billion in an all-cash deal. This significant outbound acquisition is expected to close in early 2027, strengthening Sun Pharma's global presence in women's health and biosimilars.
